Objective Corneal endothelial decompensation is caused by many corneal diseases. It often results in severe clinical complications. Endothelial keratoplasty (EK) is a new therapy for corneal endothelial decompensation. This study aimed to investigate a new approach to establishing corneal endothelial decompensation animal model with Descemetorhexis technique in order to better understand the tissue response to EK. Methods Thirty New Zealand white rabbits were randomly divided into three groups according to different surgical procedures; corneal endothelial cells (CEC), Descemet's membrane and corneal endothelial cells (DM + CEC) as well as Descemet' s stripping with endothelial keratoplasty(DSEK) group and 10 eyes for each. The right eyes of rabbits were as surgery eyes. Other 10 rabbits were as DSEK donors. Corneal transparency, anterior chamber response and graft location were examined once per day for two weeks under the slit lamp. Comeal thickness was measured by ultrasound biomicroscope. Corneal endothelial cells were analyzed using vital staining with alizarin red and trypan blue in 2, 4 and 8 weeks after operation. Results The cornea in DM + CEC group remained opaque throughout the observation period. In CEC and DSEK group, corneal clarity was gradually restored and corneal thickness was significantly less than that in the DM + CEC group during the postoperative 8 weeks. There were significant differences in corneal thickness between the DM + CEC group and CEC group or DSEK group during the postoperative 8 weeks (P ＜0. 05). The vital staining showed that most Descemetorhexis area was not covered by endothelial cells even 2 months after surgery. Conclusion A new corneal endothelial decompensation model is successfully established for the study of corneal endothelial keratoplasty, which is helpful for understanding the wound-healing of rabbit corneal endothelium after Descemel' s membrane damage.

Objective To observe the clinical effect of monosialotetrahexosyl ganglioside sodium injection (GM1) on spastic cerebral palsy. Methods 98 children with spastic cerebral palsy were randomly divided into control group (n=50) and treatment group (n=48). Both groups received Bobath approach, and the treatment group received GM1 in addition. They were assessed with Functional Independence Measure for Children (WeeFIM), Gross Motor Function Measure (GMFM) and Gesell Development Schedule (GDS) before and after 90 days of treatment. Results The scores of WeeFIM, all the dimensions of GMFM and the gross motor, fine motor, personal-social and adaption of the GDS improved in both groups after treatment (P<0.05), and improved more in the treatment group than in the control group (P< 0.05). Conclusion GM1 may further improve the recovery of function for children with spastic cerebral palsy.

Objective To explore the effect of the combined sequential application of er-lotinib between the chemotherapy periods on the treatment of the patients with advanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were collected.The pa-tients with the initial treatment were treated with gemcitabine combined with platinum for chemotherapy,while the patients with retreatment were treated with docetaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term efficacy and the adverse reactions were evaluated and compared. Results The clinical efficacy of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively (P >0.05),and the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical ef-ficacy of the patients with a history of smoking was significantly lower than that of the patients without a history of smoking (P <0.05).The clinical efficacy of the initial treatment patients with age over 65 years old was significantly higher than that of the initial treatment patients with age less than 65 years old(P <0.05).The clinical efficacy of the initial treatment patients with stage Ⅲ b was significantly higher than that of the initial treatment patients with stage Ⅳ (P <0.05).The clinical efficacy of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0 .0 5 ).The main adverse reactions were nausea ,diarrhea ,rash ,vomiting and loss of appetite .
Conclusion The clinical efficacy of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with advanced NSCLC is not such high. Smoking history,age,tumor stage and pathological type may affect its curative effect.Efficacy of this therapy in controlling the disease progress of the initial treatment patients is significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.

Objective To observe and analyze the curative effects of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with ad-vanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were se-lected as the research objects.The patients of the initial treatment were treated with gemcitabine combined with platinum for chemotherapy and the patients of retreatment were treated with doc-etaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term curative effects and the adverse reactions were evaluated and compared.Results The clinical efficiency of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively.There were no significant differences of short-term curative effects and the clinical efficiency between the initial treatment patients and the retreatment patients (P >0.05),while the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical efficiency of the patients with a smoking history was significantly lower than that of the patients without smok-ing history(P <0.05).The clinical efficiency of the initial treatment patients with age of 65 years or older was significantly higher than that of the initial treatment patients of age < 6 5 years (P <0.05).The clinical efficiency of the initial treatment patients with stage Ⅲb was signifi-cantly higher than that of the initial treatment patients with stage Ⅳ(P <0.05).The clinical ef-ficiency of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0.05).The main adverse reactions of the patients were nausea,diarrhea,rash,vomiting,loss of appetite.Conclusion The clinical efficiency of the combined sequential application of erlotinib between the chemothera-py periods in the treatment of the patients with advanced NSCLC is not high.Smoking history, age,tumor stage,pathological type may affect its curative effect.The effects of this therapy in controlling the disease progress of the initial treatment patients are more significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.

Objective To explore the effect of the combined sequential application of er-lotinib between the chemotherapy periods on the treatment of the patients with advanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were collected.The pa-tients with the initial treatment were treated with gemcitabine combined with platinum for chemotherapy,while the patients with retreatment were treated with docetaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term efficacy and the adverse reactions were evaluated and compared. Results The clinical efficacy of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively (P >0.05),and the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical ef-ficacy of the patients with a history of smoking was significantly lower than that of the patients without a history of smoking (P <0.05).The clinical efficacy of the initial treatment patients with age over 65 years old was significantly higher than that of the initial treatment patients with age less than 65 years old(P <0.05).The clinical efficacy of the initial treatment patients with stage Ⅲ b was significantly higher than that of the initial treatment patients with stage Ⅳ (P <0.05).The clinical efficacy of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0 .0 5 ).The main adverse reactions were nausea ,diarrhea ,rash ,vomiting and loss of appetite .
Conclusion The clinical efficacy of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with advanced NSCLC is not such high. Smoking history,age,tumor stage and pathological type may affect its curative effect.Efficacy of this therapy in controlling the disease progress of the initial treatment patients is significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.

Objective To observe and analyze the curative effects of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with ad-vanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were se-lected as the research objects.The patients of the initial treatment were treated with gemcitabine combined with platinum for chemotherapy and the patients of retreatment were treated with doc-etaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term curative effects and the adverse reactions were evaluated and compared.Results The clinical efficiency of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively.There were no significant differences of short-term curative effects and the clinical efficiency between the initial treatment patients and the retreatment patients (P >0.05),while the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical efficiency of the patients with a smoking history was significantly lower than that of the patients without smok-ing history(P <0.05).The clinical efficiency of the initial treatment patients with age of 65 years or older was significantly higher than that of the initial treatment patients of age < 6 5 years (P <0.05).The clinical efficiency of the initial treatment patients with stage Ⅲb was signifi-cantly higher than that of the initial treatment patients with stage Ⅳ(P <0.05).The clinical ef-ficiency of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0.05).The main adverse reactions of the patients were nausea,diarrhea,rash,vomiting,loss of appetite.Conclusion The clinical efficiency of the combined sequential application of erlotinib between the chemothera-py periods in the treatment of the patients with advanced NSCLC is not high.Smoking history, age,tumor stage,pathological type may affect its curative effect.The effects of this therapy in controlling the disease progress of the initial treatment patients are more significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.

Objective: To explore experience of wound treatment of extremely severe mass burn patients involved in August 2nd Kunshan factory aluminum dust explosion accident. Methods: On August 2nd, 2014, 98 extremely severe burn mass patients involved in August 2nd Kunshan factory aluminum dust explosion accident were admitted to 20 hospitals in China. The patients with complete medical record were enrolled in the study and divided into microskin graft group with 56 patients and Meek skin graft group with 42 patients. Split-thickness skin in area of residual skin were resected to repair wounds of patients in microskin graft group and Meek skin graft group by microskin grafting and Meek miniature skin grafting, respectively. The residual wound size on 28 days post injury and wound infection after skin grafting of patients in the two groups, and position of donor site of all patients were retrospectively analyzed. Data were processed with t test and chi-square test. Results: The size of residual wound of patients in Meek skin graft group on 28 days post injury was (59±13)% total body surface area (TBSA), which was obviously smaller than that in microskin graft group [(70±14)%TBSA, t=4.379, P<0.05]. Twenty-nine patients in microskin graft group and 11 patients in Meek skin graft group suffered from obvious wound infection after skin grafting. Wounds of patients in two groups were repaired with residual skin around wound in head, trunk, groin, armpit, and uncommon donor sites of scrotum (4 patients), vola (10 patients), and toe or finger web (8 patients). Conclusions Meek skin graft is the first choice for wound repair of extremely severe burn mass patients, with faster wound healing, less wound infection. Uncommon donor sites of scrotum, vola, and toe or finger web can also be used for wound repair in case of lack of skin.